Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

generation bio co - GBIO

GBIO

Close Chg Chg %
5.51 -0.03 -0.54%

Closed Market

5.48

-0.03 (0.54%)

Volume: 60.58K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: generation bio co - GBIO

GBIO Key Data

Open

$5.50

 Day Range

5.42 - 5.57

52 Week Range

3.00 - 10.40

 Market Cap

$36.86M

Shares Outstanding

6.74M

 Public Float

4.24M

Beta

2.05

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$9.35

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

68.88K

  

GBIO Performance

1 Week
 
 0.64%
 
1 Month
 
 0.92%
 
3 Months
 
 -10.31%
 
1 Year
 
 -40.79%
 
5 Years
 
 -98.30%
 

GBIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About generation bio co - GBIO

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

GBIO At a Glance

Generation Bio Co.
301 Binney Street
Cambridge, Massachusetts 02142
Phone 1-617-655-7500 Revenue 19.89M
Industry Pharmaceuticals: Major Net Income -131,668,000.00
Sector Health Technology 2024 Sales Growth 236.924%
Fiscal Year-end 12 / 2025 Employees 115
View SEC Filings

GBIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.55
Price to Book Ratio 0.824
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.287
Enterprise Value to Sales -1.058
Total Debt to Enterprise Value -4.446

GBIO Efficiency

Revenue/Employee 172,973.913
Income Per Employee -1,144,939.13
Receivables Turnover 12.759
Total Asset Turnover 0.066

GBIO Liquidity

Current Ratio 5.503
Quick Ratio 5.503
Cash Ratio 5.284

GBIO Profitability

Gross Margin 75.211
Operating Margin -393.817
Pretax Margin -661.914
Net Margin -661.914
Return on Assets -43.458
Return on Equity -91.015
Return on Total Capital -73.245
Return on Invested Capital -57.289

GBIO Capital Structure

Total Debt to Total Equity 108.533
Total Debt to Total Capital 52.046
Total Debt to Total Assets 40.468
Long-Term Debt to Equity 93.446
Long-Term Debt to Total Capital 44.811
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Generation Bio Co - GBIO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - 5.90M 19.89M
-
Sales Growth
- - - +236.92%
-
Cost of Goods Sold (COGS) incl D&A
4.53M 5.13M 5.26M 4.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.53M 5.13M 5.26M 4.93M
Depreciation
4.53M 5.13M 5.26M 4.93M
Amortization of Intangibles
- - - -
-
COGS Growth
+32.05% +13.20% +2.59% -6.31%
Gross Income
(4.53M) (5.13M) 641.00K 14.96M
Gross Income Growth
-32.05% -13.20% +112.50% +2,234.01%
Gross Profit Margin
- - +10.86% +75.21%
-
2021 2022 2023 2024 5-year trend
SG&A Expense
114.57M 130.95M 132.18M 93.30M
Research & Development
80.72M 86.49M 83.23M 56.07M
Other SG&A
33.85M 44.46M 48.95M 37.23M
SGA Growth
+47.48% +14.30% +0.94% -29.41%
Other Operating Expense
- - - -
-
Unusual Expense
- 5.10M 7.06M 64.31M
EBIT after Unusual Expense
(119.10M) (141.18M) (138.60M) (142.65M)
Non Operating Income/Expense
(50.00K) 4.54M 11.99M 10.98M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(119.15M) (136.64M) (126.61M) (131.67M)
Pretax Income Growth
-47.97% -14.68% +7.34% -3.99%
Pretax Margin
- - -2,144.51% -661.91%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(119.15M) (136.64M) (126.61M) (131.67M)
Minority Interest Expense
- - - -
-
Net Income
(119.15M) (136.64M) (126.61M) (131.67M)
Net Income Growth
-47.97% -14.68% +7.34% -3.99%
Net Margin Growth
- - -2,144.51% -661.91%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(119.15M) (136.64M) (126.61M) (131.67M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(119.15M) (136.64M) (126.61M) (131.67M)
EPS (Basic)
-21.1653 -23.5119 -19.6348 -19.7628
EPS (Basic) Growth
+28.36% -11.09% +16.49% -0.65%
Basic Shares Outstanding
5.63M 5.81M 6.45M 6.66M
EPS (Diluted)
-21.1653 -23.5119 -19.6348 -19.7628
EPS (Diluted) Growth
+28.36% -11.09% +16.49% -0.65%
Diluted Shares Outstanding
5.63M 5.81M 6.45M 6.66M
EBITDA
(114.57M) (130.95M) (126.28M) (73.41M)
EBITDA Growth
-47.48% -14.30% +3.57% +41.87%
EBITDA Margin
- - -2,138.80% -369.03%
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 7.50
Number of Ratings 4 Current Quarters Estimate -0.75
FY Report Date 03 / 2026 Current Year's Estimate -3.72
Last Quarter’s Earnings -5.87 Median PE on CY Estimate N/A
Year Ago Earnings -9.577 Next Fiscal Year Estimate -1.95
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 3 1
Mean Estimate -0.75 -1.01 -3.72 -1.95
High Estimates -0.11 -0.05 -0.26 -1.95
Low Estimate -1.39 -1.97 -7.05 -1.95
Coefficient of Variance -120.69 -134.41 -91.32 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 0 0 0
HOLD 2 2 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Generation Bio Co - GBIO

Date Name Shares Transaction Value
Apr 18, 2025 Cameron Geoffrey McDonough PRESIDENT AND CEO; Director 1,351,212 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Cameron Geoffrey McDonough PRESIDENT AND CEO; Director 1,349,664 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.37 per share 499,375.68
Apr 18, 2025 Cameron Geoffrey McDonough PRESIDENT AND CEO; Director 36,911 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Phillip Samayoa CHIEF SCIENTIFIC OFFICER 128,856 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Phillip Samayoa CHIEF SCIENTIFIC OFFICER 128,519 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.37 per share 47,552.03
Apr 18, 2025 Phillip Samayoa CHIEF SCIENTIFIC OFFICER 8,023 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Yalonda Howze CHIEF LEGAL OFFICER 19,720 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Yalonda Howze CHIEF LEGAL OFFICER 18,737 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.37 per share 6,932.69
Apr 18, 2025 Yalonda Howze CHIEF LEGAL OFFICER 26,774 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Antoinette Drahus Paone CHIEF OPERATING OFFICER 23,550 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Antoinette Drahus Paone CHIEF OPERATING OFFICER 23,082 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.37 per share 8,540.34
Apr 18, 2025 Antoinette Drahus Paone CHIEF OPERATING OFFICER 11,140 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Kevin Conway Chief Financial Officer 18,032 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Kevin Conway Chief Financial Officer 17,859 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.37 per share 6,607.83
Apr 18, 2025 Kevin Conway Chief Financial Officer 4,107 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Generation Bio Co in the News